论文部分内容阅读
目的探讨新研制的维甲类查尔酮酸Ｒ９１５８和ＹＳ９０４０１２联合γ干扰素（ＩＦＮγ）在急性单核细胞白血病分化疗法中的应用价值。方法应用细胞形态学、四氮唑蓝（ＮＢＴ）还原反应和非特异酯酶乙酸萘酚（ＤＣＥ）、细胞分化免疫表型ＣＤ１４和ＣＤ６８、ＣＦＵＬ集落形成抑制率等变化，体外研究其对６例急性单核细胞白血病患者白血病细胞的增殖分化作用。结果经ＹＳ９０４０１２联合ＩＦＮγ处理后，单核细胞由原始阶段变成较成熟的单核细胞，ＮＢＴ还原反应阳性率和ＤＣＥ分别由２３．４％和２５０％上升到６１．５％和５２．０％，ＣＤ１４和ＣＤ６８表达增强，ＣＦＵＬ集落增殖明显受抑。通过比较，ＹＳ９０４０１２联合ＩＦＮγ诱导细胞分化和抑制集落形成活性优于Ｒ９１５８和全反式维甲酸联合用药组（Ｐ＜０．０１）。结论ＹＳ９０４０１２联合ＩＦＮγ诱导分化治疗单核细胞白血病可能有一定临床实用价值。
Objective To investigate the value of the newly developed retinal chalcone acid R9158 and YS904012 combined with interferon-γ (IFN-γ) in the differentiation therapy of acute monocytic leukemia. Methods Cell morphology, reduction of tetrazolium blue (NBT) and non-specific esterase naphthol acetate (DCE), cell differentiation immunophenotype CD14, CD68, CFUL colony formation inhibition rate and other changes were studied in vitro. The proliferation and differentiation of leukemia cells in 6 patients with acute monocytic leukemia. Results After treated with YS904012 combined with IFN-γ, the mononuclear cells changed from primitive phase to mature monocytes. The positive rate of NBT reduction and DCE increased from 23.4% and 250% to 61.5%, respectively. 52.0%, CD14 and CD68 expression increased, CFU L colony proliferation was significantly inhibited. By comparison, YS904012 combined with IFN-γ induced cell differentiation and inhibited colony formation activity better than R9158 and all-trans retinoic acid combination group (P<0.01). Conclusion YS904012 combined with IFN γ can be used to differentiate and treat monocytic leukemia. It may have some clinical value.